Regulus Therapeutics (RGLS) News Today → Amazon's betting big on this unknown AI company (From Manward Press) (Ad) Free RGLS Stock Alerts $2.02 -0.06 (-2.88%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:40 AM | theguardian.comStarwatch: the moon celebrates with a cruise past RegulusMay 12, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Down 32.9% in AprilRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 4,210,000 shares, a decline of 32.9% from the April 15th total of 6,270,000 shares. Based on an average daily volume of 3,040,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 7.3% of the shares of the company are short sold.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429May 10, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 9, 2024 | msn.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024May 9, 2024 | prnewswire.comRegulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 8, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Rating Reiterated by HC WainwrightMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus’s Innovative ADPKD Therapy RGLS8429May 7, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by AnalystsMay 6, 2024 | marketbeat.comRegulus Therapeutics' (RGLS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday.May 6, 2024 | prnewswire.comRegulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 30, 2024 | prnewswire.comRegulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesApril 27, 2024 | marketbeat.comVivo Capital LLC Acquires New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)Vivo Capital LLC bought a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,000,000 shares of the biopharmaceutical company'sApril 10, 2024 | seekingalpha.comRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDMarch 28, 2024 | markets.businessinsider.comBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment NeedsMarch 27, 2024 | marketbeat.comShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,130,000 shares, a growth of 9,244.3% from the February 29th total of 54,900 shares. Currently, 13.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 1.8 days.March 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development MilestonesMarch 25, 2024 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday.March 23, 2024 | finance.yahoo.comRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical AdvancementsMarch 22, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 21, 2024 | investorplace.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023March 21, 2024 | finance.yahoo.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment DataMarch 15, 2024 | finance.yahoo.comRGLS Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & MoreMarch 13, 2024 | markets.businessinsider.comRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial PositionMarch 12, 2024 | marketwatch.comRegulus Therapeutics Shares Soar on Funding, Study DataMarch 12, 2024 | markets.businessinsider.comRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 MlnMarch 12, 2024 | msn.comWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?March 12, 2024 | marketbeat.comTrading was temporarily halted for "RGLS" at 11:03 AM with a stated reason of "LULD pause." Trading set to resume at 11:03 AM. March 12, 2024 | msn.comConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-BellMarch 12, 2024 | markets.businessinsider.comRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429March 12, 2024 | prnewswire.comRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityMarch 12, 2024 | prnewswire.comRegulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)February 16, 2024 | money.usnews.comRegulus Therapeutics IncJanuary 3, 2024 | msn.comRegulus concludes enrolment in Phase I trial’s third cohort for ADPKDJanuary 2, 2024 | finance.yahoo.comRegulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)December 27, 2023 | seekingalpha.comRegulus Therapeutics files for $150M mixed shelfDecember 23, 2023 | morningstar.comRegulus Therapeutics Inc RGLSNovember 22, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 11, 2023 | markets.businessinsider.comRegulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial ProgressNovember 9, 2023 | finance.yahoo.comRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNovember 2, 2023 | finance.yahoo.comRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 19, 2023 | finance.yahoo.comRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 5, 2023 | nasdaq.comRegulus Therapeutics (RGLS) Price Target Increased by 13.64% to 6.38September 22, 2023 | msn.comCanaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy RecommendationSeptember 21, 2023 | markets.businessinsider.comAnalyst Expectations for Regulus Therapeutics's FutureSeptember 20, 2023 | msn.comRegulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney DiseaseSeptember 20, 2023 | markets.businessinsider.comRegulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429September 20, 2023 | finance.yahoo.comRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Amazon's betting big on this unknown AI company (Ad)Amazon's Betting Big on This Unknown AI Company Amazon has just made a stunning $144 million investment in one small AI company. Discover why this company RGLS Media Mentions By Week RGLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼0.350.55▲Average Medical News Sentiment RGLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼91▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alimera Sciences News Rigel Pharmaceuticals News Merrimack Pharmaceuticals News Emergent BioSolutions News Bolt Biotherapeutics News XOMA News Verastem News Vanda Pharmaceuticals News Lexicon Pharmaceuticals News InterCure News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
